ABSTRACT Objective: Pregnant women with type 1 diabetes (T1D) have an increased risk of maternal-fetal complications. Regarding treatment, continuous subcutaneous insulin infusion (CSII) has advantages compared to multiple daily injections (MDI), but data about the best option during pregnancy are limited. This study's aim was to compare maternal-fetal outcomes among T1D patients treated with CSII or MDI during pregnancy. Subjects and methods: This study evaluated 174 pregnancies of T1D patients. Variables of interest were compared between the groups (CSII versus MDI), and logistic regression analysis was performed (p < 0.05). Results: Of the 174 included pregnancies, CSII was used in 21.3% (37) and MDI were used in 78.7% (137). HbA1c values improved throughout gestation in both groups, with no difference in the first and third trimesters. The frequency of cesarean section was significantly higher in the CSII group [94.1 vs. 75.4%, p = 0.017], but there was no significant difference in the frequency of other complications, such as miscarriage, premature delivery and preeclampsia. The mean birth weight and occurrence of neonatal complications were also similar, except for the proportion of congenital malformations, which was significantly lower in the CSII group [2.9 vs. 15.6%, p = 0.048]. In regression analysis, the association of CSII with cesarean section and malformations lost significance after adjusting for HbA1c and other covariates of interest. Conclusion: In this study, we observed a higher frequency of cesarean section and a lower occurrence of congenital malformations in the CSII group, but the adjusted results might indicate that these associations are influenced by glycemic control.

ABSTRACT Objective: To evaluate the association of neck circumference (NC) with gestational diabetes (GDM) and adverse outcomes in women with overweight and obesity. Subjects and methods: This prospective study included 132 (BMI > 25 kg/m2) pregnant women without and with GDM. Standardized questionnaire and biochemical/physical evaluation were performed during the 1st to 3rd trimester. Fifth-five women were evaluated regarding hypertension in pregnancy, type of delivery and neonatal complications (death, intensive care unit admission and hypoglycemia). Results: Women with (n = 61) and without (n = 71) GDM had similar mean (SD) pre-gestational BMI [30.3 (4.0) vs. 29.4 (3.5) kg/m2, p = 0.16]. Women with GDM were older [32 (6) vs. 28 (6) yrs, p < 0.001] and had greater NC [36.0 (2.7) vs. 34.5 (1.8) cm, p < 0.001]. NC was similar in women with GDM diagnosed in first or third trimester [p = 0.4] and was correlated with FPG [r 0.29, p = 0.01] and systolic [r 0.28, p = 0.001] and diastolic [r 0.25, p = 0.004] blood pressure. NC was associated with GDM [OR 1.25, 95%CI 1.03-1.52] adjusted for age, physical activity, education and familiar history of diabetes. In ROC analysis, the area under the curve was 0.655 and the cut-off value of 34.5 cm had 0.70 of sensitivity and 0.51 of specificity for GDM. Women who had NC ≥ 34.5 vs. < 34.5 cm had higher frequencies of hypertension [32.3 vs. 4.2%, p = 0.01]. Conclusions: In a group of pregnant women with overweight or obesity, NC can be a useful tool for identifying risk of GDM and obstetric adverse outcomes.

ABSTRACT Objective: Adipose tissue-derived stromal/stem cells (ASCs) and vitamin D have immunomodulatory actions that could be useful for type 1 diabetes (T1D). We aimed in this study to investigate the safety and efficacy of ASCs + daily cholecalciferol (VIT D) for 6 months in patients with recent-onset T1D. Materials and methods: In this prospective, dual-center, open trial, patients with recent onset T1D received one dose of allogenic ASC (1 x 106 cells/kg) and cholecalciferol 2,000 UI/day for 6 months (group 1). They were compared to patients who received chol-ecalciferol (group 2) and standard treatment (group 3). Adverse events were recorded; C-peptide (CP), insulin dose and HbA1c were measured at baseline (T0), after 3 (T3) and 6 months (T6). Results: In group 1 (n = 7), adverse events included transient headache (all), mild local reactions (all), tachycardia (n = 4), abdominal cramps (n = 1), thrombophlebitis (n = 4), scotomas (n = 2), and central retinal vein occlusion at T3 (n = 1, resolution at T6). Group 1 had an increase in basal CP (p = 0.018; mean: 40.41+/-40.79 %), without changes in stimulated CP after mixed meal (p = 0.62), from T0 to T6. Basal CP remained stable in groups 2 and 3 (p = 0.58 and p = 0.116, respectively). Group 1 had small insulin requirements (0.31+/- 0.26 UI/kg) without changes at T6 (p = 0.44) and HbA1c decline (p = 0.01). At T6, all patients (100%; n = 7) in group 1 were in honeymoon vs 75% (n = 3/4) and 50% (n = 3/6) in groups 2 and 3, p = 0.01. Conclusions: Allogenic ASC + VIT D without immunosuppression was safe and might have a role in the preservation of β-cells in patients with recent-onset T1D. ClinicalTrials.gov: NCT03920397.

SUMMARY Ketosis-prone type 2 diabetes (KPD) is an emerging form of diabetes mellitus characterized by unprovoked ketoacidosis, absence of autoimmunity and beta-cell dysfunction. The KPD may improve after initial glycemic compensation and evolve to exogenous insulin independence, most cases were observed in populations with African or Hispanic backgrounds. We reviewed the literature on KPD and, to date, only one case of KPD has been described in Brazil's multi-ethnic population. A group of adult Brazilian KPD patients without autoimmunity and insulinopenia was identified for this study. We report a retrospective study of four KPD cases (3 males) evaluated in southeast Brazil, the patients were overweight or obese, age between the third and fifth decades of life, had a family history of type 2 diabetes, hyperglycemia (809.5 ± 344.2 mg/dL), acidosis (pH 7.21 ± 0.07; normal range (nr): 7.35-7.45 and bicarbonate 9.1 ± 6.2; nr: 22-26 mEq/mL), ketonuria (142.5 ± 114.4 mg/dL; nr: absence), absence of glutamic acid decarboxylase antibodies (GAD-65), and beta-cell function reserve (C-peptide 1.19 ± 0.53 ng/mL - nr: 1.1-4.4 ng/mL) on diagnosis. After glycemic compensation, there was increase of C-peptide (2.21 ± 0.41) indicating the recovery of beta-cell function and the time to insulin independence was 7.7 ± 3.5 months. They evolved after the period of glucotoxicity with insulin withdrawal and could be treated with oral antidiabetic therapy. This is the first case series of KPD described in Brazil being characterized by ketoacidosis at diagnosis, absence of autoimmunity, recovery of beta-cell function and insulin independence.

ABSTRACT Objectives: The purpose of this study was to investigate the heterogeneity of the association between glycemic variability and oxidative stress markers in T1DM patients under daily life insulin treatment. Subjects and methods: We studied, in a cross-sectional analysis, 76 T1DM patients without clinical chronic diabetes complications and 22 healthy individuals. Were evaluated the short-term glycemic variability (STGV), long-term glycemic variability (LTGV), oxidative stress markers [8-isoprostaglandin-F2α (Ur-8-iso-PGF2α), nitric oxide (NO), thiobarbituric acid reactive substances (TBARS) and erythrocytes reduced/oxidized glutathione (GSH/GSSG)] and biochemical dosages (glycaemia, HbA1c, lipidogram, albuminuria). Results: Plasmatic NO was positively associated with LTGV (last year average of HbA1c) (8.7 ± 1.6% or 71 ± 18 mmol) (rS: 0.278; p: 0.042). Plasmatic TBARS, erythrocytes GSH/GSSH and Ur-8-iso-PGF-2α didn't show correlation with glycemic variability. GSH/GSSG was inversely correlated with LDL-cholesterol (rS: - 0.417; p: 0.047) and triglycerides (rS: −0.521; p: 0.013). Albuminuria was positive correlated with age (rS: 0.340; p: 0.002), plasmatic NO (rS: 0.267; p 0.049) and TBARS (rS: 0.327; p: 0.015). Conclusion: In daily life insulin treatment, young T1DM patients have higher plasmatic NO than healthy subjects. However, the correlation between glycemic variability and oxidative stress markers is heterogeneous. Lipid profile and albuminuria are associated with different oxidative stress markers. These data collaborate to explain the controversial results in this issue.

Resumo: Objetivo: avaliar o equilíbrio postural em diabéticos tipo 2 com vertigem, tontura e/ou instabilidade. Método: área do limite de estabilidade, área de deslocamento do centro de pressão e velocidade de oscilação de 20 pacientes com diabetes mellitus tipo 2 com vertigem, tontura e/ou instabilidade foram comparados a um grupo controle com 22 indivíduos hígidos à posturografia do Balance Rehabilitation Unit (BRUTM). Resultados: a área do limite de estabilidade dos diabéticos tipo 2 foi significantemente menor do que a do grupo controle. Os diabéticos tipo 2 apresentaram valores significantemente maiores quanto à área de deslocamento do centro de pressão, em superfície firme, de olhos abertos, olhos fechados e com interação visuovestibular na direção horizontal; e quanto à velocidade de oscilação em superfície firme, de olhos abertos e olhos fechados. Conclusão: diabéticos tipo 2 com vertigem, tontura e/ou instabilidade apresentam comprometimento do equilíbrio postural relacionado com estímulos visuais e de interação visuovestibular e prejuízo moderado na qualidade de vida.

Abstract: Purpose: To evaluate the postural balance of type 2 diabetics with vertigo, dizziness, and/or unsteadiness. Methods: limit of stability, pressure center displacement area, and sway velocity of 20 patients with type 2 diabetes were compared with 22 controls using the Balance Rehabilitation Unit (BRUTM, Medicaa) posturography. Results: Compared to the control group, patients with type 2 diabetes showed a significantly lower limit of stability and a significantly higher-pressure center displacement area on a firm surface with eyes open, eyes closed, and horizontal vestibular-visual interaction; and higher sway velocity on a firm surface with eyes open and with eyes closed. Conclusion: type 2 diabetics with vertigo, dizziness, and/or imbalance compromised postural balance related to visual stimuli and vestibular-visual interaction and moderate impairment in the quality of life.

RESUMO Objetivo avaliar o controle postural em indivíduos com diabetes mellitus do tipo 2 (DM2) com vertigem, tontura e/ou desequilíbrio à posturografia. Métodos pacientes com DM2, 15 do sexo feminino e cinco do masculino, idades entre 46 e 83 anos e um grupo controle de 20 indivíduos hígidos, pareados por idade e sexo, 15 do sexo feminino e cinco do masculino, idades entre 46 e 81 anos foram submetidos à versão brasileira do Dizziness Handicap Inventory (DHI) e escala visual analógica de vertigem ou tontura e posturografia estática do Tetrax IBSTM, em oito condições sensoriais. Resultados o grupo experimental apresentou prejuízo moderado na qualidade de vida ao DHI (média de 31,30 pontos) e pontuação média de 6,45 pontos na escala visual analógica de vertigem ou tontura. Houve diferença significativa entre os grupos, em todas ou algumas condições sensoriais, em relação aos valores do índice de estabilidade geral, das faixas de frequência de oscilação postural, dos índices de sincronização da oscilação postural e do índice de risco de queda. Conclusão indivíduos com DM2 com vertigem, tontura e/ou desequilíbrio podem apresentar distúrbio do controle postural à posturografia, caracterizado por alterações da estabilidade geral, sincronização da oscilação postural, faixas de frequência de oscilação postural e risco de queda, sugerindo disfunção vestibular, visual e somatossensorial, ou em sua interação no sistema nervoso central.

ABSTRACT Purpose To evaluate postural control in diabetes mellitus Type 2 patients (T2DM) with vertigo, dizziness and/or imbalance. Methods T2DM patients, 15 females and five males, ranging from 46 to 83 years old, and a control group of 20 healthy individuals with no complaints paired according to age and gender were submitted to the Brazilian version of the Dizziness Handicap Inventory (DHI), dizziness analog scale, and the Tetrax IBSTM static posturography in eight sensory conditions. Results The experimental group had moderate impairment in quality of life according to the DHI (mean of 31.30 points) and a mean score of 6.45 points in the dizziness analog scale. There was a significant difference between the groups in all or some sensory conditions concerning the values of the general stability index, frequency bands of postural oscillation, postural oscillation synchronization indexes, and the risk of falling. Conclusion T2DM patients with vertigo, dizziness and/or imbalance may present postural control impairment in posturography, characterized by changes in general stability, postural oscillation synchronization, frequency ranges of postural oscillation and risk of fall, suggesting vestibular, visual and somatosensory dysfunction or in their interaction in the central nervous system.

Diabetes has been associated with periodontitis, but the mechanisms through which periodontal diseases affect the metabolic control remain unclear. Objective: This study aimed to evaluate serum leveis of inflammatory markers, IL-8, IL-6 and monocyte chemoattractant protein 1 (MCP-1), in type 2 diabetic patients in the presence of chronic periodontitis. Material and Methods: Forty two individuals were enrolled in this study and assigned to one of five groups: diabetes mellitus with inadequate glycemic control and periodontitis (DMI+P, n = 10), diabetes mellitus with adequate glycemic control and periodontitis (DMA+P, n = 10), diabetes mellitus without periodontitis (DM, n = 10), periodontitis without diabetes (P, n=6), and neither diabetes nor periodontitis (H, n = 6). Periodontal clinical examination included visible plaque index (PL), gingival bleeding index (GB), probing depth (PD), attachment level (AL) and bleeding on probing (BP). Glycemic control was evaluated by serum concentration of glycated hemoglobin (HbAlc). Inflammatory serum markers IL-8, IL-6 and (MCP-1) were measured by ELISA. Results: DMI+P and DMA+P groups presented higher PD (p=0.025) and AL (p=0.003) values when compared to the P group. There were no significant differences among groups for IL-6, IL-8 and MCP-1 serum levels. Conclusions: Although periodontitis was more severe in diabetic patients, the serum levels of the investigated inflammatory markers did not differ among the groups.

A deficiência de vitamina D e o diabetes melito são enfermidades comuns na população e são altamente prevalentes em todas as raças, idades, regiões geográficas e situação socioeconômica. Estudos epidemiológicos mostram uma associação entre hipovitaminose D com o aumento do risco de doenças crônicas, tais como câncer, doença cardiovascular, diabetes melito do tipo 2 e doenças autoimunes como a esclerose múltipla e o diabetes mellitus do tipo 1. A identificação de receptores da 1,25(OH)2 D e da expressão da 1 α-hidroxilase nas células betapancreáticas, em células do sistema imunológico e em uma variedade de células do organismo além do tecido ósseo, suporta o papel da vitamina D na patogênese do diabetes tipo 2 e do tipo 1. Esta revisão apresenta e discute o conceito de deficiência de vitamina D, sua prevalência e seu papel na patogênese e no risco de desenvolvimento do diabetes melito e doenças cardiovasculares.

Vitamin D deficiency and diabetes mellitus are two common conditions and they are widely prevalent across all ages, races, geographical regions, and socioeconomic conditions. Epidemiologic studies have shown association of vitamin D deficiency and increased risk of chronic diseases, such as cancer, cardiovascular disease, type 2 diabetes, and autoimmune diseases, such as multiple sclerosis and type 1 diabetes mellitus. The identification of 1,25(OH)2D receptors and 1-α-hydroxilase expression in pancreatic beta cells, in cells of the immune system, and in various others tissues, besides the bone system support the role of vitamin D in the pathogenesis of type 2 diabetes. Observational studies have revealed an association between 25(OH) D deficiency and the prevalence of type 1 diabetes in children and adolescents. This review will focus on the concept of vitamin D deficiency, its prevalence, and its role in the pathogenesis and risk of diabetes mellitus and cardiovascular diseases.

OBJECTIVE: To determine the direct medical costs of type 1 diabetes mellitus (T1DM) to the National Brazilian Health-Care System (NBHCS) and quantify the contribution of each individual component to the total cost. METHODS: A retrospective, cross-sectional, nationwide multicentre study was conducted between 2008 and 2010 in 28 public clinics in 20 Brazilian cities. The study included 3180 patients with T1DM (mean age 22 years ± 11.8) who were surveyed while receiving health care from the NBHCS. The mean duration of their diabetes was 10.3 years (± 8.0). The costs of tests and medical procedures, insulin pumps, and supplies for administration, and supplies for self-monitoring of blood glucose (SMBG) were obtained from national and local health system sources for 2010-2011. Annual direct medical costs were derived by adding the costs of medications, supplies, tests, medical consultations, procedures and hospitalizations over the year preceding the interview. FINDINGS: The average annual direct medical cost per capita was 1319.15 United States dollars (US$). Treatment-related expenditure - US$ 1216.33 per patient per year - represented 92.20% of total direct medical costs. Insulin administration supplies and SMBG (US$ 696.78 per patient per year) accounted for 52.82% of these total costs. Together, medical procedures and haemodialysis accounted for 5.73% (US$ 75.64 per patient per year) of direct medical costs. Consultations accounted for 1.94% of direct medical costs (US$ 25.62 per patient per year). CONCLUSION: Health technologies accounted for most direct medical costs of T1DM. These data can serve to reassess the distribution of resources for managing T1DM in Brazil's public health-care system.

OBJETIVO: Determinar los costes médicos directos de la diabetes mellitus de tipo 1 (DMT1) para el sistema nacional brasileño de atención sanitaria (NBHCS, según sus siglas en inglés) y cuantificar la contribución de cada componente individual al coste total. MÉTODOS: Se llevó a cabo un estudio multicéntrico retrospectivo transversal a nivel nacional entre los años 2008 y 2010 en 28 clínicas públicas de 20 ciudades brasileñas. El estudio incluyó 3180 pacientes con DMT1 (edad media de 22 años ± 11,8), que fueron entrevistados mientras recibían atención sanitaria del NBHCS. La duración media de su diabetes fue de 10,3 años (± 8,0). Los costes de las pruebas y procedimientos médicos, las bombas de insulina y provisiones para la administración, así como suministros para la automonitorización de la glucosa en sangre (AMG) se obtuvieron de las fuentes de los sistemas de salud nacionales y locales para el periodo 2010-2011. Los costes médicos directos anuales se obtuvieron sumando los costes de los medicamentos, suministros, pruebas, consultas y procedimientos médicos y hospitalizaciones durante el año anterior a la entrevista. RESULTADOS: El coste medio directo anual por cápita fue de 1319,15 dólares americanos (US$). Los gastos relacionados con el tratamiento, US$ 1216,33 por paciente y año, representaron el 92,20% del total de los costes médicos directos. Los suministros para la administración de insulina y la AMG (US$ 696,78 por paciente y año) significaron el 52,82% de esos costes totales. En conjunto, los procedimientos médicos y la hemodiálisis representaron el 5,73% (US$ 75,64 por paciente y año) de los costes médicos directos. Las consultas fueron el 1,94% de los costes médicos directos (US$ 25,62 por paciente y año). CONCLUSIÓN: Las tecnologías sanitarias representaron la mayoría de los costes médicos directos de la DMT1. Estos datos pueden servir para volver a examinar la distribución de los recursos para la gestión de la diabetes de tipo 1 en el sistema de salud pública de Brasil.

OBJECTIF: Déterminer les coûts médicaux directs du diabète gras de type 1 (DT1) pour le système de santé national brésilien (SSNB) et quantifier la contribution de chaque composante individuelle au coût total. MÉTHODES: Une étude rétrospective, transversale, multicentrique et à l'échelle nationale a été menée entre 2008 et 2010 dans 28 cliniques publiques de 20 villes brésiliennes. Cette étude incluait 3180 patients atteints de DT1 (moyenne d'âge de 22 ans ± 11,8) qui ont été interrogés alors qu'ils étaient pris en charge par le SSNB. En moyenne, ils étaient atteints par la maladie depuis 10,3 ans (± 8). Les coûts des tests et des interventions médicales, des pompes à insuline et des équipements pour son administration, ainsi que des fournitures pour l'autosurveillance du taux de glycémie (ASTG) ont été obtenus à partir de sources provenant du système de santé national et local sur 2010-2011. Les coûts médicaux directs annuels ont été calculés en ajoutant les coûts des médicaments, des fournitures, des consultations médicales, des interventions et des hospitalisations au cours de l'année précédant l'enquête. RÉSULTATS: La moyenne du coût médical direct annuel par habitant s'élevait à 1319,15 dollars. Les dépenses liées au traitement - 1216,33 dollars par patient et par an -ont représenté 92,20% du total des coûts médicaux directs. L'équipement nécessaire à l'administration d'insuline et à l'ASTG (696,78 dollars par patient et par an) a totalisé 52,82% du total de ces coûts. Dans l'ensemble, les interventions médicales et l'hémodialyse ont représenté 5,73% (75,64 dollars par patient et par an) des coûts médicaux directs, et les consultations ont représenté 1,94% de ces mêmes coûts (25,62 dollars par patient et par an). CONCLUSION: Les technologies de la santé ont constitué la majeure partie des coûts médicaux directs du DT1. Ces données peuvent être utilisées pour réévaluer la distribution des ressources pour la prise en charge du DT1 par le système de santé publique brésilien.

OBJETIVO: O objetivo deste estudo foi estabelecer os melhores valores de corte para circunferência abdominal (CA), índice de massa corpórea (IMC) e HOMA-IR (HR) para identificação da concomitância de um conjunto de fatores de risco cardiovascular (> 3) em crianças e adolescentes brasileiros com tolerância normal à glicose (TNG). SUJEITOS E MÉTODOS: Estudo transversal realizado em uma cidade do sudeste do Brasil com 319 indivíduos de 10 a 19 anos de idade. Curva ROC para cada gênero foi utilizada para estabelecimento dos valores de IMC (kg/m²), CA (cm) e HRR. RESULTADOS: As áreas sob as curvas ROC para detectar o conjunto de fatores cardiovascular foram 0,92, 0,93 e 0,68 (meninas) e 0,93, 0,93 e 0,89 (meninos) para CA, IMC e HR, respectivamente. Os valores de corte foram 83,0 e 80,5 cm (CA), 22,7 e 20,4 kg/m² (IMC) e 1,65 e 1,95 (HR), para meninas e meninos, respectivamente, para detecção do grupo de fatores de risco cardiovascular. CONCLUSÃO: Esses valores de IMC,CA e HR detectaram uma porcentagem significativa de crianças e adolescentes brasileiros com TNG e elevado risco cardiovascular.

OBJECTIVE: The aim of this study was to establish the best cutoff values for waist circumference (WC), body mass index (BMI) and HOMA-IR (HR) to identify a cluster (> 3) of cardiovascular risk factors (CVRF) in normal glucose-tolerant (NGT) Brazilian children and adolescents. SUBJECTS AND METHODS: Cross-sectional study of 319 individuals (aged 10 to 19y) from a southern Brazilian city. Gender-specific receiver-operating characteristics (ROC) curves were constructed to assess cutoffs values of BMI (kg/m², WC (cm), and HR. RESULTS: The areas under the ROC curves to detect a cluster of CVRF were 0.92, 0.93 and 0.68 (females), and 0.93, 0.93 and 0.89 (males), for WC, BMI and HR, respectively. The cutoff values were 83.0 and 80.5 cm (WC), 22.7 and 20.4 kg/m2 (BMI), and 1.65 and 1.95 (HR), for females and males, respectively, to detect the cluster of CVRF. CONCLUSION: These values of BMI, WC-) and (HR) detected a high proportion of NGTt Brazilian children and adolescents with a cluster of CVRF.

OBJETIVO: Estudar a heterogeneidade e a coexistência das neuropatias no diabetes melito tipos 1 (DMT1) e 2 (DMT2). MÉTODOS: Foram avaliados 74 DMT2 e 20 DMT1 em relação à idade (anos), tempo de diagnóstico do DM (TDDM, em anos), índice de massa corpórea (IMC, kg/m²), HbA1c e tipo de neuropatia (critérios da American Diabetes Association). RESULTADOS: DMT1 era mais jovem (32,7 ± 11 versus 56,9 ± 10,3; p = 0,0001), com maior TDDM (17,1 ± 9,7 versus 10,4 ± 6,8; p = 0,003) e menor IMC (23,6 ± 3,8 versus 28,4 ± 5,3; p = 0,0005). A neuropatia autonômica cardiovascular (NAC) (60% versus 32,4%; p = 0,02) e a coexistência desta com polineuropatia (PND) (62,5% versus 33,3%; p = 0,03) foram mais prevalentes no DMT1; a PND dolorosa crônica (PNDDC) (60,8% versus 30,0%; p = 0,009) o foi no DMT2. A HbA1c (p = 0,04) foi preditiva de PND em ambos os grupos. O TDDM (p = 0,03) e a PNDDC (p = 0,003) foram preditivos de NAC no DMT1. A idade (p = 0,0004) teve valor preditivo para PNDDC no DMT2. CONCLUSÕES: As neuropatias apresentam distribuição heterogênea no DMT1 e no DMT2. Com exceção do controle glicêmico, os fatores relacionados a essa complicação diferem de acordo com o tipo de diabetes.

OBJECTIVE: To evaluate the heterogeneity and the coexistence of diabetic neuropathy (DNP) in type 1 (T1DM) and 2 (T2DM) diabetes mellitus. METHODS: 74 T2DM and 20 T1DM patients were evaluated according to age (years), time from diagnosis of diabetes (TDD, years), body mass index (BMI, kg/m²), HbA1c and DNP type (American Diabetes Association criteria). RESULTS: T1DM was younger (32.7 ± 11.0 versus 56.9 ± 10.3; p = 0.0001), leaner (BMI: 23.6 ± 3.85 versus 28.4 ± 5.3; p = 0.0005) and they had longer TDD (17.1 ± 9.7 versus 10.4 ± 6.8; p = 0.003). Cardiovascular autonomic neuropathy (CAN) (60% versus 32.4%; p = 0.02) and its coexistence with polyneuropathy (PN) (62.5% versus 33.3%; p = 0.03) were more common in T1DM. Chronic painful polyneuropathy (CPP) was more prevalent in T2DM (60.8% versus 30.0%; p = 0.009). Logistic regression showed HbA1c as an independent variable related to PN (p = 0.04) in both groups. TDD (p = 0.03) and CPP (p = 0.003) were related to CAN in T1DM. Age (p = 0.0004) was related to CPP in T2DM. CONCLUSIONS: The DNP have shown a heterogeneity distribution in type 1 and type 2 diabetes mellitus. The related factors to different phenotypes of this complication, apart from hyperglycemia, may be variable between these two types of diabetes mellitus.

FUNDAMENTO: O diabete e a doença cardiovascular emergiram como ameaças principais à saúde humana, e o risco está aumentado nos indivíduos com obesidade visceral. É consenso que o exercício físico deve fazer parte do tratamento do diabete melito (DM). OBJETIVO: Comparar a influência de programas de exercício físico orientados e estruturados (PEOE) com freqüência de três e cinco vezes por semana, no período de 20 semanas, no controle glicêmico e composição corporal de diabéticos tipo 2 (DM2). MÉTODOS: A pesquisa realizou-se na Universidade Federal de São Paulo. Grupo Controle (GC), n=17, idade (Mi: 55,8 anos), recebeu incentivo, na consulta médica, para o exercício físico. Grupo 3x (G3), n=14, idade (Mi: 57,4 anos), uma hora de exercício físico, 3x\semana. Grupo 5x (G5), n=9, idade (Mi: 58,8 anos), mesmo protocolo, mas 5x\semana. Tempo de diagnóstico: Mi: 5 anos, em todos os grupos. Aula constava de 5 min aquecimento, 30 min caminhada (esteira) a 70% da freqüência cardíaca máxima e 10 min relaxamento. IMC, cintura, porcentual de gordura (PG), glicemia capilar (Gcap), glicemia de jejum (GJ), hemoglobina glicada (HbA1c) foram avaliados. RESULTADOS: Realizou-se uma comparação entre o instante Basal (B) e 20ª semana (20ª). IMC no G3(B: 29,5±2,9 vs 20ª: 28,3±2,2 kg/m², p=0,005) e G5 (B: 29,7±4,4 vs 20ª: 29,1±4,3 kg/m², p=0,025); cintura G5 (B: 100,5±11,9 vs 20ª: 933±11,7 cm, p=0,001); PG no G3 (B: 31±5,1 vs 20ª: 26±5%, p=0,001) e G5 (B: 32,4±5,4 vs 20ª: 30,3±6,9%, p=0,001); GJ, G5 (B: 150,8±47,5 vs 20ª: 109,2±30,5 mg/dl, p=0,034), apresentaram diferenças estatisticamente significativas. GC não apresentou diferenças estatisticamente significativas, nessas variáveis. Gcap apresentou uma tendência de queda no pós-exercício físico no G5. HbA1c não apresentou diferenças estatisticamente significativas nos três grupos. CONCLUSÃO: O G5 foi melhor que o G3, na maioria dos parâmetros avaliados. Porém, os resultados não apresentaram uma diminuição na HbA1c nos pacientes com DM2.

BACKGROUND: Diabetes and cardiovascular disease have emerged as key threats to human health, and the risk is increased in individuals with visceral obesity. The consensus is that physical exercise should be part of the treatment of diabetes mellitus (DM). OBJECTIVE: To compare the influence of guided and structured physical exercise programs (SPEP), three to five times per week, during a period of 20 weeks, on glycemic control and body composition of type 2 diabetic patients (DM2). METHODS: The research was conducted at the Universidade Federal de São Paulo (Federal University School of Medicine in São Paulo). At the clinical visit, patients from the Control Group (CG) n=17, mean age 55.8 years, were encouraged to engage in a physical exercise program. Patients from Group 3x (G3), n=14, mean age 57.4 years, were to engage in 1 hour of physical exercise, 3x/week, and Group 5x (G5), n=9, mean age 58.8 years, followed the same protocol but 5x/week. Mean of 5 years since diagnosis in all groups. Classes consisted of a 5-minute warm-up, 30-minute treadmill walk at 70% of maximum heart rate, and 10-minute relaxation. BMI, abdominal circumference (AC), percentage of body fat (BF), capillary glycemia (CG), fasting glycemia (FG), and glycated hemoglobin (HbA1c) were assessed. RESULTS: A comparison was made between the baseline time point (B) and the 20th week (20th). BMI in G3 (B:29.5±2.9 vs. 20th: 28.3 ± 2.2 Kg/sqm, p=0.005) and G5 (B:29.7±4.4 vs. 20th: 29.1 ± 4.3 Kg/sqm, p=0.025); abdominal circumference in G5 (B:100.5±11.9 vs. 20th: 933 ± 11.7 cm, p=0.001); BF in G3 (B:31±5.1 vs 20th: 26±5%, p=0.001) and G5 (B:32.4 ± 5.4 vs. 20th: 30.3 ± 6.9%, p=0.001); FG, G5 (B:150.8 ± 47.5 vs. 20th: 109.2± 30.5 mg/dL, p=0.034), showed statistically significant differences. CG did not show statistically significant differences for these variables. CG showed a tendency to drop after physical exercise in G5. HbA1c showed no statistically significant differences in the three groups. CONCLUSION: G5 did better than G3 in most parameters assessed. However, results failed to show a decrease of HbA1c in DM2 patients.

FUNDAMENTO: La diabetes y la enfermedad cardiovascular surgieron como principales amenazas a la salud humana, y el riesgo crece en los individuos con obesidad visceral. Es un consenso que el ejercicio físico debe formar parte del tratamiento de la diabetes mellitus (DM). OBJETIVO: Comparar la influencia de programas de ejercicio físico orientados y estructurados (PEOE) con frecuencia de tres y cinco veces por semana, en el período de 20 semanas, en el control glucémico y la composición corporal de diabéticos tipo 2 (DM2). MÉTODOS: La investigación se realizó en la Universidad Federal de São Paulo. Grupo Control (GC), n=17, edad (edad promedio (EP): 55,8 años), recibió incentivo en la consulta médica para la realización de ejercicio físico. Grupo 3x (G3), n=14, edad (EP: 57,4 años), una hora de ejercicio físico, 3x/semana. Grupo 5x (G5), n=9, edad (EP: 58,8 años), mismo protocolo, pero 5x\semana. Tiempo de diagnóstico: EP: 5 años, en todos los grupos. La clase constaba de 5 min calentamiento, 30 min caminata en estera rodante hasta el 70% de la frecuencia cardiaca máxima y 10 min relajamiento. Se analizó IMC, cintura, porcentual de grasa (PG), glucemia capilar (GCap), glucemia de ayuno (GA), hemoglobina glucosilada (HbA1c). RESULTADOS: Se realizó una comparación entre el instante Basal (B) y la 20ª semana (20ª). Presentaron diferencias estadísticamente significativas: IMC en el G3(B: 29,5±2,9 vs 20ª: 28,3±2,2 kg/m², p=0,005) y el G5 (B: 29,7±4,4 vs 20ª: 29,1±4,3 kg/m², p=0,025); cintura G5 (B: 100,5±11,9 vs 20ª: 933±11,7 cm, p=0,001); PG en el G3 (B: 31±5,1 vs 20ª: 26±5%, p=0,001) y G5 (B: 32,4±5,4 vs 20ª: 30,3±6,9%, p=0,001); GA, G5 (B: 150,8±47,5 vs 20ª: 109,2±30,5 mg/dl, p=0,034). El GC no presentó diferencias estadísticamente significativas, en estas variables. La GCap presentó una tendencia de caída en el post ejercicio físico en G5. La HbA1c no presentó diferencias estadísticamente significativas en tres grupos. CONCLUSIÓN: En la mayoría de los parámetros evaluados, el G5 se mostró mejor que el G3. Sin embargo, los resultados no presentaron una reducción de la HbA1c en los pacientes con DM2.